Market revenue in 2022 | USD 166.6 million |
Market revenue in 2030 | USD 229.3 million |
Growth rate | 4.1% (CAGR from 2022 to 2030) |
Largest segment | Otc |
Fastest growing segment | OTC |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | OTC |
Key market players worldwide | GlaxoSmithKline, Church & Dwight Co Inc, Colgate-Palmolive Co, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceutical Industries, Lupin, Pfizer Inc, Parnell Pharmaceuticals Holdings Ltd, Acacia Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to xerostomia therapeutics market will help companies and investors design strategic landscapes.
Otc was the largest segment with a revenue share of 100% in 2022. Horizon Databook has segmented the Latin America xerostomia therapeutics market based on otc covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America xerostomia therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Latin America xerostomia therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account